Naglazyme FDA Approval History
FDA Approved: Yes (First approved May 31, 2005)
Brand name: Naglazyme
Generic name: galsulfase
Previous Name: Aryplase
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type VI
Naglazyme (galsulfase) is an enzyme-replacement therapy for treatment of mucopolysaccharidosis VI (MPS VI), an inherited, life-threatening lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B).
Development Timeline for Naglazyme
|May 31, 2005||Approval Naglazyme BioMarin Pharmaceutical Inc. - Treatment for Mucopolysaccharidosis VI (MPS VI)|
|Nov 29, 2004||BioMarin Submits U.S. Biologics License Application for Marketing Authorization of Aryplase for MPS VI|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.